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Abstract
The Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial is a multicentre,
randomised, placebo-controlled trial of magnesium sulphate (MgSO4) funded by the UK
Medical Research Council. When complete, it will be the largest single neuroprotective
study undertaken to date. Conscious patients presenting within 12 h of acute stroke with
limb weakness are eligible. The primary outcome measure is combined death and disability
as measured using the Barthel Index at 90-day follow up. By randomizing 2700 patients, the
study will have 84% power to detect a 5.5% absolute reduction in the primary end-point. By
April 2000, 86 centres were participating, with representation in Canada, USA, Europe,
South America, Singapore and Australia. So far, 1206 patients have been randomised, of
whom 37% were treated within 6 h. Overall 3-month mortality was 20% and the primary
outcome event rate was 43%. The study is ongoing and centres worldwide are encouraged
to participate.
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ADL = activities of daily living; CT = computed tomography; ICC = IMAGES Co-ordinating Centre; IMAGES = Intravenous Magnesium Efficacy in
Acute Stroke (trial); LACS = lacunar syndrome; MgSO4 = magnesium sulphate; MRI = magnetic resonance imaging; OCSP = Oxfordshire
Community Stroke Project; PACS = partial anterior circulation syndrome; POCS = posterior circulation syndrome; SAE = serious adverse event;
TACS = total anterior circulation syndrome.
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Introduction
Acute ischaemic stroke results in neurochemical and
metabolic derangements that contribute to cell death in
the ischaemic ‘penumbra’ surrounding an infarct core. The
potential viability of penumbral tissue has been affirmed by
the consistent benefit of neuroprotective treatments tar-
geted at a wide variety of metabolic derangements in the
penumbra in animal models, which lead to biochemical,
histological, radiological and functional recovery.
However, an effective neuroprotective treatment for acute
stroke in humans remains elusive.
Dose selection for neuroprotective drugs has often been
dictated by neurological or cardiovascular toxicity. Par-
enteral magnesium prevents the death of ischaemic neu-
rones in standard experimental stroke models [1,2] and
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other paradigms of ischaemic brain injury [3,4] at concen-
trations that are known to be well tolerated and safe in
humans. Because the magnesium ion is crucial to a large
number of cellular processes, the precise mechanism of
action is unknown and may be multimodal. Relevant fea-
tures may be as follows: increased cerebral blood flow
after middle cerebral arterial occlusion [5]; antivasocon-
strictor actions [6]; antagonism of calcium entry into cells
via noncompetitive blockade of the N-methyl-D-aspartate
receptor [7,8]; calcium antagonism at multiple voltage-
gated channels [9]; and enhanced recovery of vital mag-
nesium-dependent cell functions, such as adenosine
triphosphate levels and protein synthesis.
Clinical experience with MgSO4 suggests that it is a safe
treatment. In acute myocardial infarction, MgSO4 has
been administered to over 30,000 patients [10,11] with
few side effects. Intravenous or intramuscular MgSO4 is
standard treatment for the treatment of eclamptic seizures
[12,13], is superior to phenytoin as prophylaxis in pre-
eclampsia, and raises cerebrospinal fluid magnesium con-
centrations significantly (20%) [14].
In a preliminary study of 60 stroke patients [15], MgSO4
had no adverse cardiovascular effects. There was a non-
significant trend towards reduction in the proportion of
patients dead or disabled at 3 months in the magnesium-
treated group (30% versus 40%; P = 0.07). A dose-
ranging study in 25 stroke patients that compared 8, 12 or
16 mmol bolus doses, followed by a 65 mmol 24-h infu-
sion [16], confirmed that a rapid doubling of serum mag-
nesium concentrations could be achieved. The IMAGES
trial was powered to show a potentially real treatment
effect. This protocol was piloted in Glasgow, with patients
being followed up to 1-month after stroke [17]. That study
did not reveal any safety issues. A systematic review of
these and an earlier Swedish clinical trial [18] showed a
worthwhile reduction in death and disability (modified
Rankin Scale < 3), but small numbers and wide confi-
dence intervals caution against over interpretation.
Materials and methods
The IMAGES trial is a randomised, double-blind, placebo-
controlled, worldwide, multicentre collaborative trial that is
designed to test the efficacy of MgSO4 given within 12 h
of onset of clinically diagnosed acute stroke (http://www.
medther.gla.ac.uk/studies/images/index.htm). The trial is
sponsored by the UK Medical Research Council
(http://www.mrc.ac.uk). It commenced formally in October
1997, and is expected to be completed by October 2003.
In the UK the study has Multicentre Research Ethics Com-
mittee approval. Local institutional review boards have
approved it in centres across five continents.
The IMAGES Co-ordinating Centre (ICC) at the University
of Glasgow is responsible for management of the trial. The
trial database is managed by the Robertson Centre for
Biostatistics at the same site. The organisation of the trial
and scientific conduct are supervised by an appointed
Trial Steering Committee.
The Barthel Index, a measure of dependence in activities
of daily living (ADL), will be recorded during follow up by
telephone or clinic contact. Patients scoring 60 or more
will be considered independent and those scoring less
than 60 will be considered disabled. The modified Rankin
Scale will also be used as an overall measure of handicap.
Both scales have been used in a wide variety of interven-
tional stroke trials. Unblinded data have been reviewed by
an independent Data and Safety Monitoring Committee
consisting of a statistician, a neurologist and a consultant
physician. Early trial termination is only recommended if
the Data and Safety Monitoring Committee find evidence
of an adverse treatment effect or an overwhelming survival
benefit with a two-sided t test (P < 0.001).
Inclusion criteria
Conscious patients aged 18 years or older, who were pre-
viously independent, presenting within 12 h of acute
stroke with limb weakness are eligible. Patients with a
confirmed diagnosis other than ischaemic stroke, those
with known renal impairment with a serum creatinine
above 200 µmol/l (> 2.26 mg/dl), and those who are preg-
nant or with significant comorbidity are ineligible. To sim-
plify recruitment, brain imaging, formal ADL assessment or
serum creatinine levels are not required before randomisa-
tion. Stroke onset is considered to have occurred at the
time the patient was last known to be well. Patients are
considered to have been independent if they had a modi-
fied Rankin Score of 2 or less (ie can manage walking,
stair climbing, transfer and toileting alone, with a walking
stick, hand rail or with minimal assistance). Limb weakness
should have been present for at least 1 h and should be
present at the time of randomisation. Limb weakness is
considered an inability to maintain arm posture for 10 s
when held at 90° (sitting) or 45° (supine) or an inability to
maintain supine leg position for 5 s when held at 30°.
Informed consent is obtained either directly from the
patient, from a relative, or, if neither of these is available
and subject to local ethical committee approval, from an
independent clinician. Patients may withdraw from the trial
at any stage.
Exclusion criteria
Patients are ineligible if they do not fulfil the inclusion crite-
ria. Patients are not randomised if they are pregnant, if
they are suffering from a severe concomitant illness that is
likely to prevent outcome assessment, or if they are partici-
pating in another clinical trial that is likely to affect
outcome. Patients who are comatose and unable to
localise pain are ineligible. Patients with a clear indication
or contraindication for magnesium therapy are not eligible.
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Routine pretreatment serum magnesium levels are not
required. Patients with a computed tomography (CT) or
magnetic resonance imaging (MRI) proven diagnosis other
than ischaemic stroke are excluded before randomisation.
Randomisation
Patients are randomised via an automated telephone ran-
domisation service (ClinPhone Ltd, Nottingham, UK).
Treatment packs are allocated randomly by an algorithm
that utilises adaptive techniques to maintain balance on
combinations of the prognostic variables patient age, side
of stroke, Oxfordshire Community Stroke Project (OCSP)
[19] classification, and time to randomisation. The OCSP
differentiates stroke presentation into clinical prognostic
categories that relate to cerebrovascular territories. Cate-
gories include total anterior circulation events (TACS) and
partial anterior circulation events (PACS), posterior circu-
lation events (POCS) and lacunar events (LACS). The
infusion should be commenced within 30 min of treatment
allocation. Three single A4 forms are completed at the
time of randomisation and copies are mailed to the ICC;
these include one form for patient contact details, which is
faxed to the ICC within 3 days of randomisation.
Participation in the study does not inhibit the use of any
routine diagnostic investigations, thrombolytic therapy, or
therapeutic measures for secondary prevention or treat-
ment of complications. Patients have CT or MRI as soon
as possible within 7 days of admission, as recommended
by the World Health Organization European guidelines
[20], and the results are sent to the ICC. All patients are
followed up unless consent is withdrawn.
Study infusion
Each treatment pack contains MgSO4 or placebo (normal
saline) supplied as three ampoules prepared by the Sterile
Pharmacy Production Unit of the Western Infirmary,
Glasgow. The trial solutions are diluted into normal (0.9%)
saline and administered via an intravenous cannula using a
controlled-rate infusion pump. For patients receiving active
treatment, a bolus dose of 16 mmol (4 g) of MgSO4 is
infused over 15 min and then a maintenance dose of
65 mmol MgSO4 (16.25 g) is given over 24 h. Blood pres-
sure, heart rate and serious adverse events (SAEs) are
monitored at baseline, 15 min, and 12, 24 and 48 h after
infusion. Investigators are required to report any serious
event occurring up to day 7. Follow up to 48 h is recorded
on a single A4 form that is mailed to the ICC.
Follow up
Follow up is undertaken by the ICC in the UK and interna-
tionally by a centralised coordinating centre for each
country or by a local centre. Surviving patients are con-
tacted by telephone or clinic appointment at 30 ± 3 and
90 ± 7 days after the acute event. Place of residence,
modified Rankin Score, Barthel Index, drug therapy and
SAE data are routinely collected. A EuroQol EQ-5D health
assessment questionnaire is sent to surviving UK patients
after 90 ± 7 days.
Study end-points
The primary end-point of the study is the proportion of
patients dead or disabled, as assessed using Barthel
Index, at 90 ± 7 days. The use of telephone ADL assess-
ment and the dichotomous use of the Barthel score at
60/100 have been validated previously [21,22]. Sec-
ondary end-points include overall mortality alone and dis-
ability outcome by modified Rankin Score at 90 ± 7 days.
Primary end-point subgroup analysis will be undertaken for
the 1–6 h subgroup, for primary haemorrhagic and for
lacunar versus cortical stroke.
Serious adverse events
SAEs are defined as those events that are fatal, life-threat-
ening, or seriously disabling, or those that prolong/require
hospital stay. A single A4 form is completed, and faxed
immediately and then mailed to the ICC. All SAE forms are
reviewed by the coprincipal investigator. Investigators are
required to report all SAEs up to day 7, after which only
those events that are fatal and/or unexpected are to be
reported. At 30-day and 90-day follow up, only those
events that are fatal and/or unexpected are reported.
Expected events include the following: deterioration due
to initial stroke, further stroke, thrombosis, pulmonary
thromboembolism, severe pneumonia, acute myocardial
infarction and serious fall/injury. Individual investigators
may report any event that they feel is of sufficient impor-
tance and related to the trial. Details of supportive investi-
gational evidence for SAEs will help to classify diagnostic
certainty. Trial unblinding is discouraged because no spe-
cific antidote to magnesium is available and because mag-
nesium-related SAEs are considered unlikely; investigators
are able to unblind the treatment allocation independently
if toxicity is suspected.
Statistical analysis
The primary analysis will be by intention to treat. Compar-
isons of proportions of patients suffering events will be by
χ2 tests. Odds ratios and 95% confidence intervals will be
calculated using logistic regression. Adjustment for base-
line risk factors will be considered.
Sample size
This study of 2700 subjects has a power of 84% at a 5%
level of significance to detect an absolute primary end-
point reduction of 5.5%, assuming a 40% primary end-
point event rate. For the subgroup who receive treatment
within 6 h, assumed to constitute one-third of all ran-
domised subjects, or about 900 patients, there would be
80% power at the 5% level of significance to detect an
absolute reduction of 9% in death and disability, again
assuming a 40% primary end-point event rate. Under
these assumptions, the expected number of individuals
dead or disabled at 90 days is 1006, and consideration
will be given to extending the recruitment to the study until
this number of events occurs.
Results
By April 2000, 87 centres worldwide had participated
from the following countries: UK (60 centres), South
America (4), Europe (5), USA (8), Canada (3), Singapore
(2), Hong Kong (1) and Australia (4; Table 1). A total of
1206 patients had been randomised. The mean age was
71 years; 598 patients (50%) were male and 554 (48%)
had left-sided weakness.
Stroke risk factors were hypertension (51%), atrial fibrilla-
tion (20%), previous stroke/transient ischaemic attack
(29%), diabetes mellitus (17%) and ischaemic heart
disease (27%). Stroke severity at time of onset was classi-
fied for 1196 patients by the OCSP categories TACS,
PACS, LACS, POCS and unclassifiable. These were 294
(28%), 383 (36%), 336 (32%), 19 (2%) and 36 (4%),
respectively. Of 1016 CT scan reports received, 670
(66%) were reported showing infarct, 162 (16%) were
normal, 121 (12%) were haemorrhagic and 63 (6%) were
not classified.
Although 50% of patients were randomised within 6 h,
review of 984 patients showed that treatment was initi-
ated in under 3 h, 3–6 h and 7–12 h in 37 (4%), 323
(33%) and 624 (63%) of cases, respectively. Six patients
did not actually receive medication because of problems
at the time of randomisation. Difficulties with treatment
administration were reported for 103 patients, but 60%
were due to mechanical infusion problems.
A total of 447 adverse events were reported for 351
patients. Three-quarters of these were expected events
due to cerebral complications of the initial stroke (23%),
pneumonia (19%), infection (6%), further stroke (14%) or
other vascular event (13%). Although 182 adverse events
were reported during the infusion period, these were
mostly due to motor deterioration (40%), reduced level of
consciousness (15%) or pneumonia (16%).
All UK and a total of 1096 out of 1103 (99%) 3-month
follow ups were complete by April 2000. Internationally,
216/217 (99%) from Singapore, 32/36 (88%) from the
USA, 19/19 (100%) from South America, 63/64 (98%)
from Europe (excluding the UK), and 23/24 (96%) from
Australia were complete. One-month outcomes for 983
patients for death and disability (Barthel Index < 60) were
144 (15%) and 358 (36%), respectively. Three-month
outcomes for 1030 patients for death and disability
(Barthel Index < 60) were 209 (20%) and 234 (23%),
respectively. The primary outcome measure of combined
death and disability at 3 months occurred in 443 out of
1030 (43%).
Discussion
Despite the 12-h time window for recruitment of patients
with acute stroke with limb weakness, the IMAGES proto-
col has been implemented in hospitals throughout the UK
and worldwide. Although recruitment rates have been
slower that expected (Fig. 1), the study has achieved real-
istic targets. The patient cohort is comparable with those
of other large-scale neuroprotective studies. Despite a
high randomisation rate from Singapore (225/1206
[18%]), there did not appear to be a disproportionately
high rate of intracerebral haemorrhages (121/1206
[10%]), as might be expected in an oriental population.
Power calculations were based on a 40% incidence of
primary end-point at 3 months and a recruitment of one-
third of patients into the 1–6 h subgroup. So far, 37%
were treated within 6 h, and 43% of all patients were dead
or disabled at 3 months. Primary outcome at 1 month was
51%, with 20% mortality. Results were similar for sec-
ondary end-points of Modified Rankin Scale outcome at 1
and 3 months. These figures are similar to the number of
primary outcome events in the Glycine Antagonist
(gavestinel) in Neuroprotection (GAIN) international neuro-
protective study [23]: 47 and 48% at 1 and 3 months,
respectively.
Although 18% of patients experienced an adverse event
during the study infusion, conscious level was unchanged
in most cases (81%) and improved as often as it deterio-
rated. Most adverse events were related to cerebral com-
plications of the initial stroke (23%) or pneumonia (19%).
The infusion appeared to be safe. This has been con-
firmed by unblinded analysis of 1000 patients by the Data
and Safety Monitoring Committee, who recommended
continuation of the study.
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Table 1
IMAGES study patients and centre recruitment (April 2000)
Country No of centres No of patients
UK 60 800
Europe (excluding the UK) 5 93
USA 8 38
Canada 3 5
South America 4 19
Singapore 2 225
Australia 4 26
Total 87 1206
Age and OCSP classification were predictors of outcome.
The original Oxfordshire 543-patient cohort [19] sug-
gested that 6-month mortality outcomes for TACS, PACS,
LACS and POCS were 56, 10, 7 and 14%, respectively.
These data are comparable with 3-month mortality out-
comes from the IMAGES cohort by OCSP classification
(31, 25, 7 and 10%, respectively). Both age and OCSP
are used in the minimisation algorithm before randomisa-
tion, and therefore the two treatment arms are likely to be
well matched for these important prognostic parameters.
Extrapolation of current randomisation, averaging 40–50
patients per month, suggests that the study will complete
in October 2003. From a total of 87 centres, seven
centres have withdrawn because of local funding or
staffing issues. A single centre was withdrawn because of
poor recruitment rates and protocol violations. More
centres are expected to join, including a Chinese collabo-
ration. A number of recruitment strategies have been
implemented, including regular visits and distribution of
monthly newsletters.
Limited funds when compared to an industry sponsored
trial have undoubtedly limited randomisation. Trial partici-
pation is based largely on goodwill and scientific interest.
Minimal expenses will only cover basic costs of patient
randomisation. Participating sites include both district
general hospitals and academic centres. Because of the
simplicity of the trial, some centres without dedicated
research staff have still managed to randomise large
numbers of patients. The trial is compliant with the stan-
dards of good clinical practice. Many investigators have
stated that the trial has highlighted and raised the profile
of acute stroke management within their accident and
emergency department, acute medical admission ward or
dedicated stroke unit.
An additional MRI substudy is underway, and will study
treatment effects on the reduction of frequency of infarct
growth, as measured from a baseline diffusion-weighted
image volume to day 90 T2-weighted MRI volume. The
substudy is funded by the US National Institutes of Health,
and is coordinated worldwide by the University of Los
Angeles, USA. In the UK, the Scottish Chief Scientist’s
Office has funded national coordination and imaging
expenses for 50 patients. Randomizing 150 patients, the
substudy will have 80% power to detect a 25% difference
in infarct volume growth at a 5% significance level [24].
Conclusion
The IMAGES protocol is sufficiently simple to be under-
taken by busy hospital units around the world. Blinded
review of the IMAGES database has so far revealed an
adequate number of end-points. As expected, the study
infusion has remained safe. When complete, IMAGES will
be the largest single neuroprotective study. Magnesium is
potentially a safe, cheap and effective neuroprotective
treatment for acute stroke.
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Figure 1
Target and actual centre and patient recruitment rate for the IMAGES trial (April 2000).
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